NEW ORLEANS -- A polypill that combines three of the four mainstays of treatment for heart failure with reduced ejection ...

A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international ...

New findings reveal sotagliflozin's benefits for patients with heart failure with preserved ejection fraction without ...

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to ...

A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international institutions, has pooled data from 17,801 myocardial infarction survivors ...

The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction ...

In a groundbreaking medical feat, artificial intelligence guided doctors in Bengaluru to safely perform a complex lung biopsy ...

An international meta-analysis including nearly 18,000 patients from five clinical trials was coordinated by the CNIC in collaboration with institutions in four other countries ...

Heart failure with preserved ejection fraction, or HFpEF, is now the most common form of heart failure. Many people who ...

Bayer expands indication of Kerendia in India to include heart failure with preserved and mildly reduced ejection fraction: Our Bureau, Bengaluru Thursday, November 6, 2025, 17:35 ...

India is now the second country to access Bayer's Kerendia, expanding its use to treat heart failure conditions.

Background Fabry disease (FD) is an X linked lysosomal disorder with ventricular myocardial involvement that drives morbidity and mortality. Early diagnosis of cardiac involvement can be difficult.